Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Comment: Keynote 522 trial

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.09.19
Views: 510
Rating:

Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy

Prof Guiseppe Curigliano comments on data from the KEYNOTE-522 trial during a press conference at the 2019 ESMO congress.

This was a phase III trial looking at immunotherapy added to chemotherapy in early triple negative breast cancer.

Watch the press conference here

Watch Prof Peter Schmid's interview with ecancer here.

Read more about the study here

Related videos

follow us

Oncology knowledge


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation